Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
Status: | Recruiting |
---|---|
Conditions: | Blood Cancer, Blood Cancer, Hematology, Hematology |
Therapuetic Areas: | Hematology, Oncology |
Healthy: | No |
Age Range: | 18 - 80 |
Updated: | 3/6/2019 |
Start Date: | February 22, 2018 |
End Date: | March 2021 |
Contact: | Iga Sienczylo |
Email: | iga.sienczylo@unumrx.com |
Phone: | 617-945-5576 |
A Phase 1 Study of ACTR087, an Autologous T Cell Product, in Combination With SEA-BCMA, a Monoclonal Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
This is a phase 1, multi-center, single-arm, open-label study evaluating the safety,
tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell product) in
combination with SEA-BCMA (a monoclonal antibody) in subjects with relapsed or refractory
Multiple Myeloma.
tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell product) in
combination with SEA-BCMA (a monoclonal antibody) in subjects with relapsed or refractory
Multiple Myeloma.
Inclusion Criteria:
- Signed written informed consent obtained prior to study procedures
- Histologically- or cytologically-confirmed relapsed or refractory multiple myeloma
(MM) with measurable disease
- Must have received at least 3 prior lines of therapy to include treatment with a
proteasome inhibitor (eg, bortezomib, carfilzomib, or ixazomib) and an
immunomodulatory agent (eg, lenalidomide, pomalidomide) unless double-refractory to
both; and a hematopoietic stem cell transplant (HSCT), for those subjects considered
HSCT-eligible.
- Quantitative serum IgG levels for subjects with IgG MM must not exceed the
institutional upper limit of normal (ULN)
- ECOG 0 or 1
- Life expectancy of at least 6 months
- Absolute neutrophil (ANC) count greater than 1000/ µL
- Platelet count greater than 50,000/µL
- Estimated GFR >30mL/min/1.73m2
Exclusion Criteria:
- Known active central nervous system (CNS) involvement by MM
- Systemic rheumatic or autoimmune diseases or acute or chronic infections
- Uncontrolled thromboembolic events or recent severe hemorrhage
- Subjects who are currently using more than 5mg/day of prednisone (or an equivalent
glucocorticoid exceeding physiologic replacement levels)
- Prior treatment as follows:
- T cell-directed antibody therapy (eg. Alemtuzumab, anti-thymocyte globulin)
within 6 months of enrollment
- Any prior myeloma-directed therapy including cytotoxic chemotherapy, biologic
therapy, or radiotherapy within 2 weeks of enrollment
- Any mAb or other protein therapeutic containing Fc-domains within 4 weeks of
enrollment
- Experimental agents within 3 half-lives prior to enrollment, unless progression
is documented on therapy
- Prior BCMA-directed investigational agents at any time
- Prior cell or gene therapy, excluding transfers of genetically unmodified
autologous cells (eg. Hematopoietic stem cell transplantation), at any time; or
prior allogeneic HSCT at any time
- Pregnant or breastfeeding
We found this trial at
7
sites
5777 East Mayo Boulevard
Phoenix, Arizona 85054
Phoenix, Arizona 85054
(480) 515-6296
Principal Investigator: Jeremy T Larsen, MD
Phone: 480-342-6068
Mayo Clinic Mayo Clinic's campus in Arizona provides medical care for thousands of people from...
Click here to add this to my saved trials
800 Washington St
Boston, Massachusetts 02111
Boston, Massachusetts 02111
(617) 636-5000
Principal Investigator: Cindy Varga, MD
Phone: 617-636-8589
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
Click here to add this to my saved trials
4201 Belfort Road
Jacksonville, Florida 32216
Jacksonville, Florida 32216
(408) 293-2336
Principal Investigator: Sikander Ailawadhi, MD
Phone: 904-953-3376
Mayo Clinic Mayo Clinic's campus in Arizona provides medical care for thousands of people from...
Click here to add this to my saved trials
410 W 10th Ave
Columbus, Ohio 43210
Columbus, Ohio 43210
(614) 293-8652
Principal Investigator: Don Benson, MD
Phone: 614-685-6059
The Ohio State University, Wexner Medical Center Located in Columbus, The Ohio State University Wexner...
Click here to add this to my saved trials
660 Hall Street
Dallas, Texas 75246
Dallas, Texas 75246
Principal Investigator: Houston Holmes III, MD
Phone: 214-818-8325
Click here to add this to my saved trials
Indianapolis, Indiana 46237
Principal Investigator: Luke P Akard, MD
Phone: 317-528-5500
Click here to add this to my saved trials
8701 W Watertown Plank Rd
Milwaukee, Wisconsin
Milwaukee, Wisconsin
(414) 955-8296
Principal Investigator: Parameswaran Hari, MD
Phone: 414-805-8378
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
Click here to add this to my saved trials